Table A2.
Outcomes according to subgroups in the first-line setting.
| Trial ID | Tumor Type | PD-L1 Status | N | Arm A | Arm B | HR OS (95%, CI) | HR PFS (95%, CI) | SAE A | SAE B |
|---|---|---|---|---|---|---|---|---|---|
| ATTRACTION-4 | G/GEJ | All | 724 | Nivo-Chemo | Chemo | 0.9 (0.75–1.08) | 0.68 (0.51–0.90 c) | 0.579 | 0.492 |
| KEYNOTE-590 | ESCC | CPS ≥ 10 | NA | Pembro-Chemo | Chemo | 0.57 (0.43–0.75) | NA | NA | NA |
| ESCC | All | 547 | Pembro-Chemo | Chemo | 0.72 (0.60–0.88) | 0.65 (0.54–0.78) | NA | NA | |
| ESCC/EGJ | CPS ≥ 10 | NA | Pembro-Chemo | Chemo | 0.62 (0.49–0.78) | 0.51 (0.41–0.65) | NA | NA | |
| ESCC/EGJ | All | 749 | Pembro-Chemo | Chemo | 0.73 (0.62–0.86) | 0.65 (0.55–0.76) | 0.72 | 0.68 | |
| CheckMate 649 | G/GEJ/EAC | CPS ≥ 1 | 1296 | Nivo-Chemo | Chemo | 0.77 (0.64–0.92 a) | NA | NA | |
| G/GEJ/EAC | CPS ≥ 5 | 955 | Nivo-Chemo | Chemo | 0.71 (0.59–0.86 b) | 0.68 (0.56–0.81 d) | 0.59 | 0.44 | |
| G/GEJ/EAC | All | 1581 | Nivo-Chemo | Chemo | 0.8 (0.68–0.94 a) | NA | NA | ||
| KEYNOTE-062 | G/GEJ | CPS ≥ 1 | 506 | Pembro | Chemo | 0.91 (0.74–1.10) | 1.66 (1.37–2.01) | 0.169 | 0.693 |
| G/GEJ | CPS ≥ 10 | 182 | Pembro | Chemo | 0.69 (0.49–0.97) | 1.1 (0.79–1.51) | NA | NA | |
| G/GEJ | CPS ≥ 1 | 507 | Pembro-Chemo | Chemo | 0.85 (0.70–1.03) | 0.84 (0.70–1.02) | 0.732 | 0.693 | |
| G/GEJ | CPS ≥ 10 | 189 | Pembro-Chemo | Chemo | 0.85 (0.62–1.17) | 0.73 (0.53–1) | NA | NA |
a 99.3% CI, b 98.4% CI, c 98,51% CI, d 98% CI. ESCC = esophageal squamous cell carcinoma; G = gastric; GEJ = gastroesophageal junction; EAC = esophageal adenocarcinoma.